MSLN Primary Antibody

Item Information
Catalog # Size/Concentration Price
31741 100ug $341.00
Specification
AliasesMPF; SMRP
Clone#4H12F8
Entrez GeneID10232
FormulationPurified antibody in PBS with 0.05% sodium azide
HostMouse
IsotypeIgG1
ImmunogenMouse IgG1
MW69kDa
Application
ELISA1/10000
IHC_P (Immunohistochemistry) Purified recombinant fragment of human MSLN (AA: 37-286) expressed in E. Coli.
FCM (Flow Cytometry)1/200 - 1/400
Sequence
(AA: 37-286) expressed in E. Coli.
Catalog
31741
$341.00
-
+

Contact us to order

Images

Figure 1: Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)

Cell Culture Products

Figure 2: Western blot analysis using MSLN mAb against human MSLN (AA: 37-286) recombinant protein. (Expected MW is 52.7 kDa)

Cell Culture Products

Figure 3: Western blot analysis using MSLN mAb against HEK293 (1) and MSLN (AA: 37-286)-hIgGFc transfected HEK293 (2) cell lysate.

Cell Culture Products

Figure 4: Flow cytometric analysis of Hela cells using MSLN mouse mAb (green) and negative control (red).

Cell Culture Products
Tissue Array Results
Position Tissues Name Result Localization
Nucleus Cytoplasm Membrane
E9/10 Endometrial Cancer
View Full Documents
Product Overview
Description

This gene encodes a preproprotein that is proteolytically processed to generate two protein products, megakaryocyte potentiating factor and mesothelin. Megakaryocyte potentiating factor functions as a cytokine that can stimulate colony formation of bone marrow megakaryocytes. Mesothelin is a glycosylphosphatidylinositol-anchored cell-surface protein that may function as a cell adhesion protein. This protein is overexpressed in epithelial mesotheliomas, ovarian cancers and in specific squamous cell carcinomas. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed.

References (references)
References (references) 1.Tumour Biol. 2018 Oct;40(10):1010428318804937.
2.Mol Cancer. 2017 Mar 14;16(1):63.

Please view FAQs here